A startup developing a drug discovery platform capable of simultaneously measuring intracellular signals over time using proprietary technology, addressing multi-factor and multi-target drug discovery. Accelerating efficient and comprehensive new drug development through high-dimensional data and AI analysis.
With more than 30 years of experience in developing tactile and sensory measurement technologies, Jun Wada founded Hapquitous in 2023 upon turning 60. Guided by the mission of “bringing the potential of sensation and perception to anyone, anywhere,” Hapquitous developed Pain Compass®, a novel device based on the Thermal Grill Illusion (TGI). The system provides a three-minute assessment that objectively evaluates stress-related hypersensitivity in the brain and visualizes presenteeism—conditions that typically remain hidden in the workplace. Hapquitous offers an integrated solution that connects measurement → intervention (acupuncture, exercise, psychological support) → follow-up assessment, enabling early detection and improvement of employee well-being. Hapquitous is currently conducting collaborative research with ten institutions, including Kyoto Tachibana University, Kio University, and the University of Tokyo School of Medicine.
Cerebro Pharma was established in 2020 as an Osaka-based bio-venture with the mission to create a society free of dementia. We focus on research and development of healthcare products and pharmaceuticals specializing in the prevention and improvement of dementia and neurodegenerative diseases, and actively promote collaborative projects with major domestic pharmaceutical companies and academic institutions.
We operate “Doboku Sensei,” a web platform for civil engineering stakeholders that shares new methods and technologies to build sustainable, community-based infrastructure maintenance systems. By connecting municipalities with local communities, we establish a framework for transferring technical expertise and reducing maintenance costs.
A startup developing kidney disease treatments and cell therapies using iPS cell technology, expanding its achievements in the kidney disease field while advancing applications to the liver and pancreas.